Disseminated Adenovirus After Transplant: Cidofovir's Certainty or Brincidofovir's Safer Profile
A single patient, a child three weeks past a cord-blood transplant, with adenovirus now detectable in his blood and his liver enzymes climbing. The disagreement is between the drug with the longer track record and the one built specifically to avoid its most dangerous side effect.
Eli T., an 8-year-old boy who received a cord-blood transplant three weeks ago for severe combined immunodeficiency, has spent most of his hospital stay parked in front of a tablet propped against his IV pole, working through an animated series with his older sister on video calls between doses. He developed watery diarrhea a week ago, initially attributed to his conditioning regimen, and adenovirus was detected in his stool by PCR two days later — a common enough finding after HSCT that isn't automatically treated on its own. Today's repeat labs changed that calculus: adenovirus is now detectable in his blood by quantitative PCR, and his ALT has more than tripled from his admission baseline. Disseminated disease, not isolated gut shedding, is what those two findings together describe, and disseminated adenovirus in a pediatric HSCT recipient this early post-transplant carries real, described mortality risk if it isn't brought under control.
Cidofovir has the longer track record and the most direct evidence of viral clearance in this setting, but its dose-limiting toxicity is proximal renal tubular injury, serious enough that every dose requires aggressive IV hydration and probenecid co-administration — a real burden in a small child whose kidneys are already navigating post-transplant nephrotoxin exposure from his calcineurin inhibitor. Brincidofovir, a lipid-conjugated prodrug engineered specifically to avoid cidofovir's renal handling and its resulting nephrotoxicity, carries its own real cost instead — GI toxicity and hepatotoxicity in a meaningful share of treated patients — and its outcomes data specifically for adenovirus rest largely on AdVise, the Grimley trial in transplant recipients, which never carried the drug to an adenovirus indication — brincidofovir's own approval is for smallpox, so using it here means an investigational or expanded-access route rather than a prescription, a practical fact that sits alongside the evidentiary one. His already-rising ALT is the detail sharpening that tradeoff: is it safe to reach for the drug whose own signature toxicity lands on an organ already showing early strain? What no dataset supplies is the comparison the team actually wants. Cidofovir and brincidofovir have never been randomized against each other for adenovirus in children, so a choice between a known renal toxicity and a known hepatic one has to be made on which organ is already complaining rather than on which drug performs better.
Pediatric HSCT rounds, week three
I'd start cidofovir with a full nephroprotective protocol — aggressive IV hydration, probenecid with every dose. It has the deepest, most direct track record for clearing disseminated adenovirus specifically, and disseminated disease in a pediatric HSCT recipient this early is dangerous enough that I'd rather lean on the more proven agent when its known risk has a well-established mitigation protocol.
A nephroprotective protocol is not a guarantee, and I don't want to be heard promising one. It is a reason to think we have room, not a reason to think we have none to lose.
I'd reach for brincidofovir instead. His kidneys are already navigating tacrolimus exposure — his creatinine is mildly elevated for age right now, not zero strain — and cidofovir's nephrotoxicity is well-documented in its own labeling even with hydration and probenecid. When a real alternative mechanism exists specifically to avoid that renal handling, I don't think "manageable with a protocol" is the same as "no added risk."
I'm not disputing cidofovir's efficacy data — I'm saying a nephroprotective protocol reduces risk, it doesn't eliminate it, and stacking any additional renal strain on a child whose kidney function is already trending the wrong way is a real cost even if it's a manageable one.
I'd point to a detail neither of you has centered yet: it's his ALT that's more than tripled, not his creatinine, which is only mildly elevated. Cidofovir's toxicity is renal, not hepatic — it doesn't add meaningful risk to the organ actually showing strain right now. Brincidofovir's real hepatotoxicity signal lands directly on the organ that's already trending the wrong way.
I'd frame this as organ-specific rather than "which drug is generally safer" — on today's labs specifically, that framing favors cidofovir with nephroprotection, not because brincidofovir is a bad drug, but because its own toxicity happens to target exactly where he's already showing strain.
Agreed: cidofovir started with a full nephroprotective protocol, renal function and ALT both monitored daily, and adenovirus PCR quantified twice weekly to track response.
Not fully closed: the nephrologist's underlying concern — that "manageable with a protocol" understates real added renal risk — was heard and not dismissed, only outweighed by the clinical pharmacologist's organ-specific reading of today's labs. The team agreed explicitly that a switch to brincidofovir returns to the table if his creatinine begins trending upward despite nephroprotection, rather than treating today's choice as fixed regardless of how he responds.